From the Department of Radiology, Mount Sinai Medical Center, 4300 Alton Rd, Miami Beach, FL 33140.
Radiographics. 2020 Jan-Feb;40(1):200-222. doi: 10.1148/rg.2020190070.
Neurodegenerative diseases are a devastating group of disorders that can be difficult to accurately diagnose. Although these disorders are difficult to manage owing to relatively limited treatment options, an early and correct diagnosis can help with managing symptoms and coping with the later stages of these disease processes. Both anatomic structural imaging and physiologic molecular imaging have evolved to a state in which these neurodegenerative processes can be identified relatively early with high accuracy. To determine the underlying disease, the radiologist should understand the different distributions and pathophysiologic processes involved. High-spatial-resolution MRI allows detection of subtle morphologic changes, as well as potential complications and alternate diagnoses, while molecular imaging allows visualization of altered function or abnormal increased or decreased concentration of disease-specific markers. These methodologies are complementary. Appropriate workup and interpretation of diagnostic studies require an integrated, multimodality, multidisciplinary approach. This article reviews the protocols and findings at MRI and nuclear medicine imaging, including with the use of flurodeoxyglucose, amyloid tracers, and dopaminergic transporter imaging (ioflupane). The pathophysiology of some of the major neurodegenerative processes and their clinical presentations are also reviewed; this information is critical to understand how these imaging modalities work, and it aids in the integration of clinical data to help synthesize a final diagnosis. Radiologists and nuclear medicine physicians aiming to include the evaluation of neurodegenerative diseases in their practice should be aware of and familiar with the multiple imaging modalities available and how using these modalities is essential in the multidisciplinary management of patients with neurodegenerative diseases.RSNA, 2020.
神经退行性疾病是一组具有破坏性的疾病,其诊断难度较大。尽管由于治疗选择相对有限,这些疾病难以治疗,但早期和正确的诊断有助于控制症状并应对疾病后期。解剖结构成像和生理分子成像都已发展到可以相对较早且准确地识别这些神经退行性过程的阶段。为了确定潜在的疾病,放射科医生应该了解不同的分布和涉及的病理生理过程。高空间分辨率 MRI 可以检测到细微的形态变化,以及潜在的并发症和其他诊断,而分子成像可以显示功能改变或疾病特异性标志物的异常增加或减少。这些方法是互补的。适当的检查和诊断研究的解释需要综合、多模态、多学科的方法。本文回顾了 MRI 和核医学成像的方案和结果,包括使用氟脱氧葡萄糖、淀粉样蛋白示踪剂和多巴胺转运蛋白成像(碘氟苯)。一些主要的神经退行性过程的病理生理学及其临床表现也进行了回顾;了解这些成像方式的工作原理,以及将临床数据整合起来帮助综合最终诊断,这一点至关重要。希望将神经退行性疾病的评估纳入其实践的放射科医生和核医学医师应该了解并熟悉多种可用的成像方式,以及如何使用这些方式对于神经退行性疾病患者的多学科管理至关重要。RSNA,2020 年。